HIV and hepatitis delta virus: Evolution takes different paths to relieve blocks in transcriptional elongation

Microbes and Infection

Volumn 4, Issue 11, 2002, Pages 1169-1175

  Yamaguchi, Yuki ^a,c   Deléhouzée, Sophie ^a   Handa, Hiroshi ^b  

^a Graduate School of Bioscience and Biotechnology   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Hepatitis delta antigen; Hepatitis delta virus; Human immunodeficiency virus; RNA polymerase II; Tat; Transcriptional elongation

Indexed keywords

CELL PROTEIN; DRB SENSITIVITY INDUCING FACTOR; ELONGATION FACTOR; ELONGATION FACTOR ELONGIN; ELONGATION FACTOR TFIIF; ELONGATION FACTOR TFIIS; HEPATITIS B SURFACE ANTIGEN; HEPATITIS DELTA ANTIGEN; HEPATITIS DELTA ANTIGEN L; HEPATITIS DELTA ANTIGEN S; MESSENGER RNA; NEGATIVE ELONGATION FACTOR; POSITIVE TRANSCRIPTION FACTOR B; RNA POLYMERASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN FUNCTION; CHRONIC LIVER DISEASE; EVOLUTION; GENE STRUCTURE; HEPATITIS DELTA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LIFE CYCLE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MESSENGER RNA SYNTHESIS; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION; VIRUS GENOME; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSCRIPTION;

EVOLUTION, MOLECULAR; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, TAT; HEPATITIS DELTA ANTIGENS; HEPATITIS DELTA VIRUS; HIV; HUMANS; MODELS, BIOLOGICAL; MODELS, GENETIC; MODELS, STRUCTURAL; RNA POLYMERASE II; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ELONGATION FACTORS;

HEPATITIS DELTA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036753656     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(02)01641-6     Document Type: Review

References (56)

1. Fiedler U., Marc Timmers H.T. Peeling by binding or twisting by cranking: models for promoter opening and transcription initiation by RNA polymerase II. Bioessays. 22:2000;316-326.
2. Conaway J.W., Conaway R.C. Transcription elongation and human disease. Annu. Rev. Biochem. 68:1999;301-319.
3. Uptain S.M., Kane C.M., Chamberlin M.J. Basic mechanisms of transcript elongation and its regulation. Annu. Rev. Biochem. 66:1997;117-172.
4. Conaway J.W., Shilatifard A., Dvir A., Conaway R.C. Control of elongation by RNA polymerase II, Trends. Biochem. Sci. 25:2000;375-380.
5. Yamaguchi Y., Wada T., Handa H. Interplay between positive and negative elongation factors: drawing a new view of DRB. Genes. Cells. 3:1998;9-15.
6. Price D.H. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol. Cell. Biol. 20:2000;2629-2634.
7. Wada T., Takagi T., Yamaguchi Y., Ferdous A., Imai T., Hirose S., Sugimoto S., Yano K., Hartzog G.A., Winston F., Buratowski S., Handa H. DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs. Genes Dev. 12:1998;343-356.
8. Wada T., Takagi T., Yamaguchi Y., Watanabe D., Handa H. Evidence that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II-dependent transcription in vitro. EMBO J. 17:1998;7395-7403.
9. Yamaguchi Y., Takagi T., Wada T., Yano K., Furuya A., Sugimoto S., Hasegawa J., Handa H. NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell. 97:1999;41-51.
10. Yamaguchi Y., Inukai N., Narita T., Wada T., Handa H. Evidence that negative elongation factor represses transcription elongation through binding to a DRB sensitivity-inducing factor/RNA polymerase II complex and RNA. Mol. Cell. Biol. 22:2002;2918-2927.
11. Marshall N.F., Peng J., Xie Z., Price D.H. Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J. Biol. Chem. 271:1996;27176-27183.
12. Renner D.B., Yamaguchi Y., Wada T., Handa H., Price D.H. A highly purified RNA polymerase II elongation control system. J. Biol. Chem. 276:2001;42601-42609.
13. Ivanov D., Kwak Y.T., Guo J., Gaynor R.B. Domains in the SPT5 protein that modulate its transcriptional regulatory properties. Mol. Cell. Biol. 20:2000;2970-2983.
14. Ping Y.H., Rana T.M. DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation. J. Biol. Chem. 276:2001;12951-12958.
15. Parada C.A., Roeder R.G. A novel RNA polymerase II-containing complex potentiates Tat-enhanced HIV-1 transcription. EMBO J. 18:1999;3688-3701.
16. Kim J.B., Yamaguchi Y., Wada T., Handa H., Sharp P.A. Tat-SF1 protein associates with RAP30 and human SPT5 proteins. Mol. Cell. Biol. 19:1999;5960-5968.
17. Frankel A.D., Young J.A. HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem. 67:1998;1-25.
18. Jones K.A., Peterlin B.M. Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63:1994;717-743.
19. Karn J. Tackling Tat. J. Mol. Biol. 293:1999;235-254.
20. Garber M.E., Jones K.A. HIV-1 Tat: coping with negative elongation factors. Curr. Opin. Immunol. 11:1999;460-465.
21. Palangat M., Meier T.I., Keene R.G., Landick R. Transcriptional pausing at +62 of the HIV-1 nascent RNA modulates formation of the TAR RNA structure. Mol. Cell. 1:1998;1033-1042.
22. Pessler F., Hernandez N. The HIV-1 inducer of short transcripts activates the synthesis of 5,6-dichloro-1-β-d-benzimidazole-resistant short transcripts in vitro. J. Biol. Chem. 273:1998;5375-5384.
23. Kao S.Y., Calman A.F., Luciw P.A., Peterlin B.M. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature. 330:1987;489-493.
24. Marciniak R.A., Calnan B.J., Frankel A.D., Sharp P.A. HIV-1 Tat protein trans-activates transcription in vitro. Cell. 63:1990;791-802.
25. Wei P., Garber M.E., Fang S.M., Fischer W.H., Jones K.A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell. 92:1998;451-462.
26. Zhu Y., Pe'ery T., Peng J., Ramanathan Y., Marshall N., Marshall T., Amendt B., Mathews M.B., Price D.H. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev. 11:1997;2622-2632.
27. Mancebo H.S., Lee G., Flygare J., Tomassini J., Luu P., Zhu Y., Peng J., Blau C., Hazuda D., Price D., Flores O. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev. 11:1997;2633-2644.
28. Jeang K.T., Xiao H., Rich E.A. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J. Biol. Chem. 274:1999;28837-28840.
29. Weiss M.A., Narayana N. RNA recognition by arginine-rich peptide motifs. Biopolymers. 48:1998;167-180.
30. Greenbaltt J., Nodwell J.R., Mason S.W. Transcriptional antitermination. Nature. 364:1993;401-406.
31. Rana T.M., Jeang K.T. Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA. Arch. Biochem. Biophys. 365:1999;175-185.
32. Rizzetto M., Canese M.G., Arico S., Crivelli O., Trepo C., Bonino F., Verme G. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 18:1977;997-1003.
33. Lai M.M. The molecular biology of hepatitis delta virus. Annu. Rev. Biochem. 64:1995;259-286.
34. Lazinski D.W., Taylor J.M. Recent developments of hepatitis delta virus research. Adv. Virus Res. 43:1994;187-231.
35. Polish L.B., Gallagher M., Fields H.A., Hadler S.C. Delta hepatitis: molecular biology and clinical and epidemiological features. Clin. Microbiol. Rev. 6:1993;211-229.
36. Casey J.L. Hepatitis delta virus. Genetics and pathogenesis. Clin. Lab. M. 16:1996;451-464.
37. Ryu W.S., Netter H.J., Bayer M., Taylor J. Ribonucleoprotein complexes of hepatitis delta virus. J. Virol. 67:1993;3281-3287.
38. Wang K.S., Choo Q.L., Weiner A.J., Ou J.H., Najarian C., Thayer R.M., Mullenbach G.T., Denniston K.J., Gerin J.L., Houghton M. Structure, sequence and expression of the hepatitis delta viral genome. Nature. 323:1986;508-513.
39. Makino S., Chang M.F., Shieh C.K., Kamahora T., Vannier D.M., Govindarajan S., Lai M.M. Molecular cloning and sequencing of a human hepatitis delta (δ) virus RNA. Nature. 329:1987;343-346.
40. Kos A., Dijkema R., Arnberg A.C., van P.H., der Merde, Schellekens H. The hepatitis delta (δ) virus possesses a circular RNA. Nature. 323:1986;558-560.
41. Reid C.E., Lazinski D.W. A host-specific function is required for ligation of a wide variety of ribozyme-processed RNAs. Proc. Natl. Acad. Sci. USA. 97:2000;424-429.
42. MacNaughton T.B., Gowans E.J., McNamara S.P., Burrell C.J. Hepatitis delta antigen is necessary for access of hepatitis delta virus RNA to the cell transcriptional machinery but is not part of the transcriptional complex. Virology. 184:1991;387-390.
43. Fu T.B., Taylor J. The RNAs of hepatitis delta virus are copied by RNA polymerase II in nuclear homogenates. J. Virol. 67:1993;6965-6972.
44. Filipovska J., Konarska M.M. Specific HDV RNA-templated transcription by pol II in vitro. RNA. 6:2000;41-54.
45. Moraleda G., Taylor J., Host. RNA polymerase requirements for transcription of the human hepatitis delta virus genome. J. Virol. 75:2001;10161-10169.
46. Polson A.G., Bass B.L., Casey J.L. RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase. Nature. 380:1996;454-456.
47. Yamaguchi Y., Filipovska J., Yano K., Furuya A., Inukai N., Narita T., Wada T., Sugimoto S., Konarska M.M., Handa H. Stimulation of RNA polymerase II elongation by hepatitis delta antigen. Science. 293:2001;124-127.
48. Aso T., Lane W.S., Conaway J.W., Conaway R.C. Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science. 269:1995;1439-1443.
49. Shilatifard A., Lane W.S., Jackson K.W., Conaway R.C., Conaway J.W. An RNA polymerase II elongation factor encoded by the human ELL gene. Science. 271:1996;1873-1876.
50. Lee C.Z., Lin J.H., Lai M.M.C. RNA-binding activity of hepatitis delta antigen involves two arginine-rich motifs and is required for hepatitis delta virus RNA replication. J. Virol. 67:1993;2221-2227.
51. Glenn J.S., Watson J.A., Havel C.M., White J.M. Identification of a prenylation site in delta virus large antigen. Science. 256:1992;1331-1333.
52. Otto J.C., Casey P.J. The hepatitis delta virus large antigen is farnesylated both in vitro and in animal cells. J. Biol. Chem. 271:1996;4569-4572.
53. Hwang S.B., Lai M.M. Isoprenylation masks a conformational epitope and enhances trans-dominant inhibitory function of the large hepatitis delta antigen. J. Virol. 68:1994;2958-2964.
54. Lee C.H., Chang S.C., Wu C.H., Chang M.F. A novel chromosome region maintenance 1-independent nuclear export signal of the large form of hepatitis delta antigen that is required for the viral assembly. J. Biol. Chem. 276:2001;8142-8148.
55. Hwang S.B., Lai M.M. Isoprenylation mediates direct protein-protein interactions between hepatitis large delta antigen and hepatitis B virus surface antigen. J. Virol. 67:1993;7659-7662.
56. Beard M.R., MacNaughton T.B., Gowans E.J. Identification and characterization of a hepatitis delta virus RNA transcriptional promoter. J. Virol. 70:1996;4986-4995.